Compare ZSTK & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZSTK | ADVB |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | Canada | United States |
| Employees | 21 | 31 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 10.1M |
| IPO Year | N/A | N/A |
| Metric | ZSTK | ADVB |
|---|---|---|
| Price | $4.01 | $4.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.4K | ★ 75.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.72 | $0.19 |
| 52 Week High | $11.00 | $7.70 |
| Indicator | ZSTK | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 37.39 |
| Support Level | $3.72 | $3.67 |
| Resistance Level | $5.86 | $5.71 |
| Average True Range (ATR) | 0.75 | 0.78 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 29.44 | 0.00 |
ZeroStack Corp is an AI focused asset management company. The company also operates a world-wide Commercial and wholesale business through its wholly owned subsidiary. ZeroStack is focused on providing exposure to decentralized AI through a concentrated digital asset approach structured to generate yield and fee-based income from staking validators, compute power technology companies, and complementary businesses within the ecosystem and across the wider AI landscape. The other segment commercial and wholesale (Phatebo and TruHC), which sell pharmaceutical products and mix of products across multiple categories including food and beverage, cannabis accessories and technology, personal care and wellness.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.